EBITDA add-backs: what to support, what to challenge and what to subtract

A practical evidence framework for normalization, including owner compensation and missing recurring costs.

Educational owner resource. Read the cited sources and obtain advice for your circumstances.

An adjustment is a claim about future operations

An add-back is more than an expense you would prefer a buyer to overlook. It claims that an amount reduced historical earnings and will not be needed in the ongoing operation. For each proposed item, record the accounting period, ledger account, amount, invoice or payroll evidence, reason for adjustment and the expected future treatment. That file helps distinguish a supported change from an optimistic assertion.

Use separate columns for reported, proposed and agreed earnings. Your initial schedule should be open to challenge. A buyer can accept the existence of an expense while disagreeing that it disappears. Keeping disagreement visible avoids quietly presenting an unconfirmed number as settled.

Owner pay needs a replacement-cost allowance

Suppose, entirely fictionally, that payroll contains $170,000 for a working owner. If the ongoing business needs a pharmacist-manager at an assumed fully loaded cost of $150,000, only the $20,000 excess is a candidate adjustment under that assumption. Adding back the entire salary would leave required labour unpaid. Include benefits, coverage and the actual scope of the role when considering replacement cost.

Also ask whether the owner performs purchasing, bookkeeping, deliveries or relationship management outside the scheduled pharmacist hours. Those tasks may require separate support. A purchaser planning to do the work personally can have a different cash-flow view, but do not blur that view with a standalone normalized EBITDA figure. SDE and EBITDA serve different purposes; name the metric you use.

Recurring problems are not one-time costs

A discrete, documented legal matter might be a candidate if it has ended and is not part of ordinary operations. Repeated recruitment costs, equipment maintenance or compliance spending should not vanish merely because invoices arrive irregularly. Be equally careful with renovations: a capital cost is not necessarily an expense in EBITDA, and necessary future investment still affects a buyer’s planning.

Personal expenses require particular care. First verify they actually reduced reported earnings and identify any associated tax or accounting issue with your accountant. Do not count the same cost in multiple categories. Unsupported cash claims, hypothetical future growth and a buyer’s hoped-for purchasing savings are not evidence of historical standalone earnings.

Make negative adjustments just as visible

Under-market related-party rent, unfilled relief shifts, missing insurance or necessary software subscriptions can require deductions. Owner dependence sometimes produces both an excess-compensation add-back and an additional coverage deduction; the logic must identify distinct costs rather than double count. The objective is a realistic operating picture, not the highest number.

Normalization must consider both positive and negative adjustments. The examples above are planning illustrations, not compensation evidence for your store. Smith & Bederman Advisory Group Use the calculator to organize candidates, keep evidence status unconfirmed until reviewed, and ask your accountant or valuation advisor to assess the complete bridge. A supported lower number is a better planning foundation than an unsupported higher one.

Continue reading

Pharmacy financial figures: gross profit, gross margin, NOI and EBITDA

Pharmacy share or asset purchase agreement: what sellers should expect

Selling a pharmacy in Canada: what happens from an accepted offer to closing?

Sources and context

S&B proposed valuation planning assumptions
Owner-requested 4–8× scenario range and proposed geographic estimates. Not a published comparable-sales dataset, appraisal or independently verified market range. The website link identifies S&B; it is not external evidence for these figures.

Browse all articles and exit guides →

Plan your next conversation

Smith & Bederman Advisory Group supports independent Canadian pharmacy owners with sales, acquisitions, valuation and succession planning.

Explore valuation and EBITDA tools · Check exit readiness · Book a confidential consultation

Calculator access, full buyer profiles and downloads are available through the Resource Centre’s access form.